{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T17:46:06Z","timestamp":1777311966863,"version":"3.51.4"},"update-to":[{"DOI":"10.1002\/14651858.cd009354.pub4","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2019,6,18]],"date-time":"2019-06-18T00:00:00Z","timestamp":1560816000000}}],"reference-count":37,"publisher":"Wiley","issue":"4","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd009354.pub5","type":"journal-article","created":{"date-parts":[[2019,6,18]],"date-time":"2019-06-18T14:42:38Z","timestamp":1560868958000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Enzyme replacement therapy with laronidase (Aldurazyme\u00ae) for treating mucopolysaccharidosis type I"],"prefix":"10.1002","volume":"2021","author":[{"given":"Elisabeth","family":"Jameson","sequence":"additional","affiliation":[{"name":"Willink Biochemical Genetics Unit, Manchester Centre for Genomic Medicine; Central Manchester University Hospitals NHS Foundation Trust; Manchester UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"Jones","sequence":"additional","affiliation":[{"name":"Willink Biochemical Genetics Unit, Manchester Centre for Genomic Medicine; Central Manchester University Hospitals NHS Foundation Trust; Manchester UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tracey","family":"Remmington","sequence":"additional","affiliation":[{"name":"Department of Women's and Children's Health; University of Liverpool; Liverpool UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2019,6,18]]},"reference":[{"issue":"1","key":"10.1002\/14651858.CD009354.pub5-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1542\/peds.2007-3847","article-title":"Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I","volume":"123","author":"Clarke","year":"2009","journal-title":"Pediatrics"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD009354.pub5-BIB0002|cit2","first-page":"28","article-title":"A phase 3 extension study of aldurazyme (laronidase) in mucopolysaccharidosis I (MPS I)","volume":"29","author":"Clarke","year":"2006","journal-title":"Journal of Inherited Metabolic Disease"},{"issue":"Suppl C","key":"10.1002\/14651858.CD009354.pub5-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"S111","DOI":"10.1016\/S0149-2918(07)80472-3","article-title":"A phase III extension study of aldurazyme(laronidase) in mucopolysaccharidosis I","volume":"29","author":"Clarke","year":"2007","journal-title":"Clinical Therapeutics"},{"key":"10.1002\/14651858.CD009354.pub5-BIB0004|cit4","unstructured":"Clinical Study of Aldurazyme in Patients With Mucopolysaccharidosis (MPS) I clinicaltrials.gov\/ct2\/show\/NCT00912925"},{"issue":"5","key":"10.1002\/14651858.CD009354.pub5-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.jpeds.2004.01.046","article-title":"Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase)","volume":"144","author":"Wraith","year":"2004","journal-title":"Journal of Pediatrics"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD009354.pub5-BIB0006|cit6","first-page":"182","article-title":"Aldurazyme (laronidase) enzyme replacement therapy for MPS I: 96-week extension data","volume":"28","author":"Wraith","year":"2005","journal-title":"Journal of Inherited Metabolic Disease"},{"issue":"2","key":"10.1002\/14651858.CD009354.pub5-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1016\/j.ymgme.2014.12.049","article-title":"A study of intrathecal enzyme replacement for cognitive decline in mucopolysaccharidosis I","volume":"114","author":"Chen","year":"2015","journal-title":"Molecular Genetics and Metabolism"},{"issue":"2","key":"10.1002\/14651858.CD009354.pub5-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1016\/j.ymgme.2013.12.054","article-title":"Intrathecal enzyme replacement for cognitive decline in mucopolysaccharidosis type I","volume":"111","author":"Chen","year":"2014","journal-title":"Molecular Genetics and Metabolism"},{"issue":"2","key":"10.1002\/14651858.CD009354.pub5-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1016\/j.ymgme.2012.11.052","article-title":"A study of intrathecal enzyme replacement for cognitive decline in mucopolysaccharidosis I","volume":"108","author":"Chen","year":"2013","journal-title":"Molecular Genetics and Metabolism"},{"issue":"1-2","key":"10.1002\/14651858.CD009354.pub5-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1016\/j.ymgme.2016.11.063","article-title":"A randomized open-label clinical trial of intrathecal recombinant human alpha-L-iduronidase for cognitive decline in mucopolysaccharidosis type i","author":"Chen","year":"2017","journal-title":"Molecular Genetics and Metabolism"},{"issue":"55","key":"10.1002\/14651858.CD009354.pub5-BIB0011|cit11","first-page":"1","article-title":"Enzyme replacement therapy and \/ or hematopoietic stem cell transplantation at diagnosis in patients with mucopolysaccharidosis type I: results of a European consensus procedure","volume":"6","author":"Rue","year":"2011","journal-title":"Orphanet Journal of Rare Disease"},{"issue":"1","key":"10.1002\/14651858.CD009354.pub5-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ymgme.2008.10.009","article-title":"A dose-optimisation trial of laronidase (Aldurazyme) in patients with mucopolysaccharidosis I","volume":"96","author":"Giugliani","year":"2009","journal-title":"Molecular Genetics and Metabolism"},{"issue":"2","key":"10.1002\/14651858.CD009354.pub5-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1097\/01.GIM.0000154299.22120.6A","article-title":"Safety and efficacy of enzyme replacement therapy in combination with hematopoietic stem cell transplantation in Hurler syndrome","volume":"7","author":"Grewal","year":"2005","journal-title":"Genetics in Medicine"},{"issue":"3","key":"10.1002\/14651858.CD009354.pub5-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1056\/NEJM200101183440304","article-title":"Enzyme-replacement therapy in mucopolysaccharidosis I","volume":"344","author":"Kakkis","year":"2001","journal-title":"New England Journal of Medicine"},{"issue":"7","key":"10.1002\/14651858.CD009354.pub5-BIB0015|cit15","first-page":"776","article-title":"Enzyme replacement therapy for the mucopolysaccharidoses","volume":"14","author":"Kakkis","year":"2001","journal-title":"Journal of Inherited Metabolic Disease"},{"issue":"10","key":"10.1002\/14651858.CD009354.pub5-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1001\/archopht.125.10.1353","article-title":"Ocular changes in patients with mucopolysaccharidosis I receiving enzyme replacement therapy","volume":"125","author":"Pitz","year":"2007","journal-title":"Archives of Ophthalmology"},{"issue":"Issue 1 Suppl","key":"10.1002\/14651858.CD009354.pub5-BIB0017|cit17","article-title":"Intrathecal alpha-L-iduronidase protects from or improves neurodevelopmental decline and neuroimaging abnormalities of children with MPS I below 6 years","volume":"38","author":"Salehpour","year":"2015","journal-title":"Journal of Inherited Metabolic Disease"},{"issue":"1","key":"10.1002\/14651858.CD009354.pub5-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.1542\/peds.2006-2156","article-title":"Enzyme replacement therapy in patients who have mucopolysaccharidosis I and are younger than 5 years: results of a multinational study of recombinant human alpha-L-iduronidase (laronidase)","volume":"120","author":"\u00a0Beck","year":"2007","journal-title":"Pediatrics"},{"issue":"1","key":"10.1002\/14651858.CD009354.pub5-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jpeds.2008.07.004","article-title":"Use of enzyme replacement therapy (Laronidase) before hematopoietic stem cell transplantation for mucopolysaccharidosis I: experience in 18 patients","volume":"154","author":"Wynn","year":"2009","journal-title":"Journal of Pediatrics"},{"key":"10.1002\/14651858.CD009354.pub5-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1164\/ajrccm.152.3.7663792","article-title":"Standardization of spirometry, 1994 update. American Thoracic Society","volume":"152","author":"American Thoracic Society","year":"1995","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD009354.pub5-BIB0021|cit21","unstructured":"Visual Rx. Online NNT Calculator www.nntonline.net\/"},{"issue":"18","key":"10.1002\/14651858.CD009354.pub5-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1001\/archinte.160.18.2835","article-title":"The Gaucher registry: demographics and disease characteristics of 1698 patients with Gaucher disease","volume":"160","author":"Charrow","year":"2000","journal-title":"Archives of Internal Medicine"},{"issue":"1","key":"10.1002\/14651858.CD009354.pub5-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1542\/peds.2007-3847","article-title":"Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I","volume":"123","author":"Clarke","year":"2009","journal-title":"Pediatrics"},{"issue":"6","key":"10.1002\/14651858.CD009354.pub5-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1007\/s00431-011-1644-x","article-title":"Diagnosis and treatment in mucopolysaccharidosis I: findings from the MPS I Registry","volume":"171","author":"D'Aco","year":"2012","journal-title":"European Journal of Pediarics"},{"key":"10.1002\/14651858.CD009354.pub5-BIB0025|cit25","unstructured":"Aldurazyme \u00ae (Laronidase) www.aldurazyme.com\/pdf\/az_us_hc_pi.pdf"},{"key":"10.1002\/14651858.CD009354.pub5-BIB0026|cit26","unstructured":"Higgins JPT Altman DG Sterne JAC on behalf of the Cochrane Statistical Methods Group and the Cochrane Bias Methods Group Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook of Systematic Reviews of Interventions. Version 5.1 [updated March 2011] The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org 2011"},{"issue":"7414","key":"10.1002\/14651858.CD009354.pub5-BIB0027|cit27","first-page":"557","article-title":"Measuring inconsistencies in meta-analyses","volume":"327","author":"Higgins","journal-title":"2003"},{"key":"10.1002\/14651858.CD009354.pub5-BIB0028|cit28","unstructured":"Deeks JJ Higgins JPT Altman DG on behalf of the Cochrane Statistical Methods Group Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook of Systematic Reviews of Interventions. Version 5.1 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org 2011"},{"issue":"3","key":"10.1002\/14651858.CD009354.pub5-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1001\/jama.281.3.249","article-title":"Prevalance of lysosomal storage disorders","volume":"281","author":"Meikle","year":"1999","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD009354.pub5-BIB0030|cit30","unstructured":"MPS I Registry www.lsdregistry.net\/mpsiregistry\/"},{"issue":"1","key":"10.1002\/14651858.CD009354.pub5-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1542\/peds.2008-0416","article-title":"Mucolpolysaccharidosis I: management and treatment guidelines","volume":"123","author":"Muenzer","year":"2009","journal-title":"Pediatrics"},{"key":"10.1002\/14651858.CD009354.pub5-BIB0032|cit32","first-page":"3421","volume-title":"The Metabolic and Molecular Bases of Inherited Disease","author":"Neufeld","year":"2001"},{"key":"10.1002\/14651858.CD009354.pub5-BIB0033|cit33","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2011"},{"issue":"4","key":"10.1002\/14651858.CD009354.pub5-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/01.GIM.0000078027.83236.49","article-title":"Can mucopolysaccharidosis type I disease severity be predicted based on a patient's genotype? A comprehensive review of the literature","volume":"5","author":"Terlato","year":"2003","journal-title":"Genetics in Medicine"},{"issue":"2","key":"10.1002\/14651858.CD009354.pub5-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S0002-9343(02)01150-6","article-title":"Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry","volume":"113","author":"Weinreb","year":"2002","journal-title":"American Journal of Medicine"},{"issue":"11","key":"10.1002\/14651858.CD009354.pub5-BIB0036|cit36","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009354.pub3","article-title":"Enzyme replacement therapy with laronidase (Aldurazyme\u00ae) for treating mucopolysaccharidosis type I","author":"Jameson","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD009354.pub5-BIB0037|cit37","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009354.pub4","article-title":"Enzyme replacement therapy with laronidase (Aldurazyme\u00ae) for treating mucopolysaccharidosis type I","author":"Jameson","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD009354.pub5\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T04:48:25Z","timestamp":1666846105000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD009354.pub5"}},"subtitle":[],"editor":[{"name":"Cochrane Cystic Fibrosis and Genetic Disorders Group","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2019,6,18]]},"references-count":37,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,4]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd009354.pub5","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,18]]}}}